Welcome to the CytRx Corporation Securities Litigation Settlement Website This website has been established to provide general information regarding the proposed Settlement of the consolidated action entitled In re CytRx Corporation ("CytRx") Securities Litigation, No. 2:14-CV-01956-GHK-PJW, pending...
CytRx Corporation (Nasdaq: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics to treat patients with high unmet needs. CytRx's most advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has ...
CytRx Corporation (CYTR).Presents an interview with Steven A. Kriegsman, director, president and CEO of CytRX Corp., a biotechnology and biopharmaceutical company. Financial performance; Products being developed by the company; Reasons that should compel investors to include CytRX in their ...
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes two programs in clinical development for cancer indications: aldoxorubicin (formerly known as INNO-206) and tamibarotene. With its tumor-targeted doxorubicin conjugate ald...
LOS ANGELES, July 11, 2016 /PRNewswire/ --CytRxCorporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the results of an analysis of its global, randomized, Phase 3 clinical trial ofaldoxorubicincompared to investigator's choice therap...
Clinical researchPhase IIIEvents MORE ON THIS TOPIC Vaccines FDA Pauses Study of BioNTech’s Malaria Shot as Problems for Vaccine Space Mount March 5, 2025 · 2 min read · Tristan Manalac Cancer BeiGene Gets Yet Another Label Expansion f...
Get the latest CytRx Corporation (CYTR) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.
CytRx Announces Plan To Initiate A Phase 2 Clinical Trial With INNO-206 As A Treatment For Advanced Pancreatic CancerCytRx Announces Plan To Initiate A Phase 2 Clinical Trial With INNO-206 As A Treatment For Advanced Pancreatic CancerCytRx Corporation...
CYTRX CORPORATION.Analyzes the stock prices and stock market performance of Cytrx Corp. for April 2001. Range of price fluctuations; Recommendations.EBSCO_bspEquities Special Situations
CytRx Corporation.A company profile of CytRx Corporation is presented.EBSCO_bspCytrx Corporation Marketline Company Profile